ADVANCED MOLECULAR DIAGNOSTICS – GENETIC TESTING
InteliMed Health is a proud partner of Admera Health, an advanced molecular diagnostics company focused on personalized medicine, non-invasive cancer testing and digital health. Dedicated to developing cutting-edge diagnostics that span the continuum of care, Admera Health fulfills unmet medical needs with cost-effective tests and accurate analysis to guide patient care. Utilizing next generation technology platforms and advanced bioinformatics, Admera Health seeks to redefine disease screening, diagnosis, treatment, monitoring, and management through its innovative, personalized solutions. It is our mission to deliver transformative, valuable solutions for patients, physicians, and clinical researchers. We are committed to improving the health and well-being of our global community through the direct delivery of personalized, medically actionable results.
PGxOne™ Plus Pharmacogenomics Test
PGxOne™ Plus is a pharmacogenomics test that predicts how patients will respond to drug therapy based on their individual genetic makeup. Differences between individuals can affect drug absorption, metabolism, or activity. Therefore, while one treatment regimen may work well for one individual, the same regimen may cause adverse effects for other individuals.1, 2 PGxOne™ Plus comprehensively screens 50 well-established pharmacogenomic genes in a single, cost-effective test that provides medically actionable and clinically relevant data, thus allowing physicians to make effective treatment decisions. Expanding beyond pharmacogenomics, PGxOne™ Plus reports potential adverse interactions of the patient’s current medications.
PGxOneTM Plus Sample Reports and Informational Sheet
Cardiovascular Genetic Test Portfolio
Developed by Admera Health and Health In Code, AtheroGxOne™ is a comprehensive NGS based genetic test to detect mutations in 84 genes responsible for monogenic diseases of early atherosclerosis. These diseases include:
- Premature coronary artery disease (men < 50 years old; women < 60 years old)
- Familial Hypercholesterolemia
- Familial Hypertriglyceridemia
- Mixed Hyperlipidemias
In addition, the panel screens for mutations related to Maturity-Onset Diabetes of the Young (MODY).
AtheroGxOne™ Informational Sheet
The CardioGxOneTM panel is a comprehensive NGS based molecular test for inherited cardiovascular diseases. Developed by Admera Health and Health In Code, the test detects genomic variations in 213 genes related to cardiovascular diseases and provides cardiologists and other physician specialists with clear genetic interpretation for risk assessment and disease diagnosis.
Specific Disease Panels:
PGxCardio™ Cardiovascular Pharmacogenomics Test
PGxCardio™ is a pharmacogenomics test that helps predict how a patient will respond to cardiac drug therapy based on their individual genetic background, which can affect drug absorption, metabolism, and activity.
This test can be ordered by itself or paired with the AtheroGxOne™ and CardioGxOne™ as a reflex test based on results, providing essential information to help guide effective treatment decisions and potentially reduce adverse drug events.
Genes included: ABCB1 • ACE • ADRA2A • AGTR1 • APOE • CYP2C19 • CYP2C9 • CYPD26 • CYP3A4 • CYP3A5 • CYP4F2 • KIF6 • NAT1 • NOS1AP • SLCO1B1 • VKORC1
PGxCardioTM Sample Report and Informational Sheet
Aortic Vascular Diseases
Thoracic aortic aneurysms and dissections include a group of diseases with different physiopathological mechanisms triggering the occurrence of each of them. Among these pathologies are the following genetic syndromes: Marfan, familial thoracic aortic aneurysms and dissections (TAAD), Loeys-Dietz, Ehlers-Danlos and Shprintzen-Goldberg; all of them are inherited following an autosomal dominant pattern. Penetrance and expressivity are variable, depending on the type of syndrome and on other factors such as age of onset of the disease, location of the aneurysm and degree of dilatation of the aorta before dissection.
Inherited Cardiovascular Diseases and Sudden Death General Panel
Cardiomyopathies, channelopathies, congenital heart diseases, aortic vascular diseases, skeletal myopathy, pulmonary hypertension and familial dyslipidemias.
This panel includes all genes associated or potentially associated with the development of inherited cardiovascular diseases that can present sudden death as a major adverse event. It should be considered when an exhaustive study of all genes related to cardiovascular pathologies is intended, especially in cases of sudden death where clinical or pathological information is incomplete or the diagnosis is unclear. The genetic testing in these cases serves as a guide and should be complemented with an exhaustive family evaluation.